| Literature DB >> 28639945 |
Tolga Han Efe, Mehmet Doğan1, Cem Özişler, Tolga Çimen, Mehmet Ali Felekoğlu, Ahmet Göktuğ Ertem, Engin Algül, Sadık Açıkel.
Abstract
OBJECTIVE: Systemic lupus erythematosus (SLE) is a chronic, inflammatory, and autoimmune connective tissue disease. One of the leading causes of mortality among SLE patients is pulmonary hypertension. The aim of this study was to evaluate the association between echocardiographic findings, including the pulmonary pulse transit time and pulmonary hypertension parameters, in SLE patients.Entities:
Mesh:
Year: 2017 PMID: 28639945 PMCID: PMC5689055 DOI: 10.14744/AnatolJCardiol.2017.7666
Source DB: PubMed Journal: Anatol J Cardiol ISSN: 2149-2263 Impact factor: 1.596
Figure 1Pulmonary pulse transit time is defined as the time interval between the R-wave peak in the ECG and corresponding peak late-systolic pulmonary vein flow velocity. It is depicted in the figure between 2 parallel vertical red lines
Demographic and clinical features of the SLE and control groups
| Variables | SLE group (n=30) | Control group (n=34) | |
|---|---|---|---|
| Age, years | 39.9±11 | 37.9±11.5 | 0.47 |
| Fasting glucose, mg/dL | 87.4± 8.2 | 94.1±27.7 | 0.18 |
| Hemoglobin, g/dL | 13.3±1.1 | 13.2±1.1 | 0.75 |
| Creatinine, mg/dL | 0.79±0.13 | 0.82±0.12 | 0.37 |
| BMI, kg/m2 | 25.1±4.9 | 25.6±4.5 | 0.65 |
| Age at diagnosis | 35.0 ±15.4 | ||
| Disease duration, month | 121.1±49.9 | ||
| Hydroxychloroquine | 100% (30) | ||
| Steroids | 46.7% (14) | ||
| NSAIDs | 13.3% (4) | ||
| Immunosuppressive | 16.7% (5) |
BMI - body mass index; N - number; NSAIDs - nonsteroidal anti-inflammatory drugs
Distribution of SLE disease activity index (SLEDAI)*
| SLEDAI Score | Percentage (N) |
|---|---|
| 1 | 16.7% (5) |
| 2 | 43.3% (13) |
| 3 | 6.7% (2) |
| 4 | 23.3% (7) |
| 5 | 6.7% (2) |
| 6 | 3.3% (1) |
N: Number;
Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH.
Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992; 35: 630–640. PMID: 1599520
Echocardiographic features of the SLE and control groups
| Variables | SLE group (n=30) | Control group (n=34) | |
|---|---|---|---|
| EF, % | 66.8±3.7 | 67.1±3.5 | 0.73 |
| IVSd, mm | 9.1±1.4 | 9.5±1 | 0.22 |
| LVPWd, mm | 9±1.5 | 9.4±1.1 | 0.26 |
| LA, mm | 31.6±4.7 | 31.2±3.7 | 0.71 |
| RV MPI | 0.48±0.07 | 0.43±0.09 | 0.026 |
| TAPSE, mm | 23.4±3.7 | 25.3±2.4 | 0.021 |
| ePASP, mm Hg | 23±3.3 | 20.9±4.3 | 0.036 |
| pPTT, ms | 174.1±30.1 | 196.1±27.8 | 0.003 |
| HR, bpm | 80.6±7.3 | 77.5±10.2 | 0.17 |
EF - ejection fraction; ePASP - estimated pulmonary artery systolic pressure; HR - heart rate; IVSd - diastolic interventricular septum diameter; LA - left atrial diameter; LVPWd - diastolic left ventricular posterior wall diameter; pPTT - pulmonary pulse transit time; RV MPI - right ventricular myocardial performance index; TAPSE - Tricuspid Annular Plane Systolic Excursion.
Statistically significant
Correlation coefficients between echocardiographic parameters and pulmonary pulse transit time
| r | ||
|---|---|---|
| BMI | -0.143 | 0.260 |
| Disease duration | -0.593 | 0.001 |
| MPI | -0.262 | 0.037 |
| ePASP | -0.423 | 0.020 |
| TAPSE | 0.525 | <0.001 |
| SLEDAI2 | 0.249 | 0.185 |
| Age | 0.034 | 0.787 |
BMI - body mass index; ePASP - estimated pulmonary artery systolic pressure; MPI - right ventricular myocardial performance index; SLEDAI2 - SLE disease activity index; TAPSE - Tricuspid Annular Plane Systolic Excursion
Figure 2Matrix scatter plot graph representing correlation between clinical /echocardiographic parameters and pulmonary pulse transit time